Biopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations.
Jillian Scaife
Advertisement
Articles by Jillian Scaife
Advertisement
Latest Updated Articles
- Challenges to the Specialty Business Model
June 17th 2014
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection
2
When Ambition Meets Ambiguity: The Trends and Sentiments Shaping Biotech in 2026
3
FDA Reveals New Guidance for Streamlining Biosimilar Development
4
What Risks and Opportunities Does FDA's Single-Trial Approval Pathway Create?
5